These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17960324)

  • 1. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
    Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
    Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
    Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
    Watanabe T; Kato H; Kobayashi Y; Yamasaki S; Morita-Hoshi Y; Yokoyama H; Morishima Y; Ricker JL; Otsuki T; Miyagi-Maesima A; Matsuno Y; Tobinai K
    Cancer Sci; 2010 Jan; 101(1):196-200. PubMed ID: 19817748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Vansteenkiste J; Van Cutsem E; Dumez H; Chen C; Ricker JL; Randolph SS; Schöffski P
    Invest New Drugs; 2008 Oct; 26(5):483-8. PubMed ID: 18425418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
    O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
    J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
    Bradley D; Rathkopf D; Dunn R; Stadler WM; Liu G; Smith DC; Pili R; Zwiebel J; Scher H; Hussain M
    Cancer; 2009 Dec; 115(23):5541-9. PubMed ID: 19711464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
    J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
    Goncalves PH; Heilbrun LK; Barrett MT; Kummar S; Hansen AR; Siu LL; Piekarz RL; Sukari AW; Chao J; Pilat MJ; Smith DW; Casetta L; Boerner SA; Chen A; Lenkiewicz E; Malasi S; LoRusso PM
    Oncotarget; 2017 May; 8(20):32918-32929. PubMed ID: 28415633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
    Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
    Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
    Goldstein LJ; Zhao F; Wang M; Swaby RF; Sparano JA; Meropol NJ; Bhalla KN; Pellegrino CM; Katherine Alpaugh R; Falkson CI; Klein P; Sledge GW
    Breast Cancer Res Treat; 2017 Sep; 165(2):375-382. PubMed ID: 28623430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
    Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
    J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat in solid and hematologic malignancies.
    Siegel D; Hussein M; Belani C; Robert F; Galanis E; Richon VM; Garcia-Vargas J; Sanz-Rodriguez C; Rizvi S
    J Hematol Oncol; 2009 Jul; 2():31. PubMed ID: 19635146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
    Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
    J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.